6results about How to "Inhibitory function" patented technology

This invention discloses the application of ITPRIPL1 as a biomarker for the diagnosis or prognosis of gastric cancer. Database analysis revealed high expression of ITPRIPL1 in gastric cancer patients. Immunohistochemical staining of samples from clinically diagnosed gastric cancer patients further validated its high expression in gastric cancer tumor cells, with higher ITPRIPL1 expression levels observed in lower-differentiated tumor tissues. This invention provides a novel biomarker for the diagnosis and prognosis of gastric cancer, offering new ideas and directions for immunotherapy of gastric cancer.

The application provides a battery and a power utilization device, which comprise a negative electrode sheet, the negative electrode sheet comprises a nickel element, the mass content of the nickel element is X, and the volume median particle size of the negative electrode active material is H; an electrolyte comprises a first additive, a second additive and a third additive, the mass percentage content of the first additive is A, the mass percentage content of the second additive is B, and the mass percentage content of the third additive is C; the values of A, B, C, H and X satisfy the following conditions: 0.001 <= (A+B) / X <= 0.83; 0.2 <= (A+B+C) / H <= 3.06; 0.18 <= C / (A+B) <= 3.2; in the application, (A+B) / X ensures the balance between the total amount of the additive and the pollution degree for the nickel impurity interface; (A+B+C) / H realizes the matching between the chemical protection of the additive and the negative electrode particle size; C / (A+B) balances the proportion of the basic film forming and the interface stable protection; the interface side reaction and the SEI film instability problem caused by the migration of the nickel element dissolution are effectively inhibited, so that the battery realizes the optimal balance between the thermal shock safety, the low-temperature cycle and the high-temperature cycle performance.

The invention belongs to the technical field of medical instruments, and particularly discloses an anti-tumor electrospinning stent and a preparation method thereof. The drug-loaded electrospinning stent is characterized by comprising a drug-loaded electrospinning stent main body and tumor cell-derived drug-loaded microparticles loaded on the surface of the drug-loaded electrospinning stent main body. The drug-loaded electrospinning stent main body comprises an amino polymer, a hydrophilic polymer and celecoxib which are prepared by using an electrospinning technology and have a mass ratio of (2-10): (2-13): 1, and the drug-loaded electrospinning stent main body has high specific surface area and high porosity; the loading capacity of the tumor cell source doxorubicin-loaded microparticles on the anti-tumor electrospinning bracket is 0.6 mu g / mg to 6.1 mu g / mg. The drug is directly delivered to a tumor resection cavity in an in-situ implantation mode, and long-acting drug retention, continuous drug release and complete degradation of a stent material are achieved. The tumor immune microenvironment is remodeled while residual tumor cells are effectively killed, and recurrence and metastasis of tumors are inhibited.

The invention opens up a brand new application field of the composition formed by the diosmin and the PD-1 inhibitor, and provides a potential, effective, safe and economical new treatment scheme for gastric cancer patients, especially patients intolerant or drug-resistant to traditional chemotherapy. The invention proves that diosmin can effectively and specifically inhibit the activity of NUAK1 kinase and further inhibit a Wnt / beta-catenin signal channel at the downstream of the NUAK1 kinase. The effect is directly shown as that the protein expression levels of key transcription factors TCF4 and LEF1 are remarkably reduced, so that the function of diosmin serving as a novel NUAK1 inhibitor is proved on the molecular mechanism level, and the tumor inhibition effect of the composition formed by diosmin and the PD-1 inhibitor is remarkably superior to that of the PD-1 inhibitor.

The invention discloses application of isofulvic alcohol in preparation of a medicine for preventing and treating clostridium perfringens infection, and belongs to the field of biological medicine. A clostridium perfringens sliding motion inhibition test, a biofilm formation inhibition test, a growth curve test and a mouse gas gangrene model treatment test prove that the isofulvic alcohol can obviously inhibit the function of clostridium perfringens IV type fimbriae (TFP) and has no bactericidal or antibacterial activity on clostridium perfringens. An in-vivo infection model treatment test shows that the isofulvic alcohol has a good prevention and treatment effect on the clostridium perfringens gas gangrene of mice. The invention provides a theoretical basis for using the isofulvic alcohol to prevent and treat the clostridium perfringens infection, increases the selectivity of the medicine for preventing and treating the clostridium perfringens infection, has a wide application prospect, and is of great significance to the development of new medicines.

The application discloses a low-temperature tolerance related GLUR6 gene of Pomacea canaliculata, an encoding protein and application thereof, and belongs to the technical field of biotechnology.The nucleotide sequence of the GLUR6 gene is shown as SEQ ID NO:1; the GLUR6 gene can be applied as a target for pesticide screening and biological control of Pomacea canaliculata. The application further provides dsRNA of the GLUR6 gene. The green and environment-friendly biological pesticide developed according to the dsRNA sequence can reduce the survival rate of Pomacea canaliculata in a low-temperature environment and the hatching rate of Pomacea canaliculata eggs. The application is fast, effective and highly reproducible, and is an important supplement to the GLUR6 gene family. The application reduces the low-temperature tolerance of Pomacea canaliculata by blocking the expression of the GLUR6 gene in Pomacea canaliculata, so as to achieve the purpose of controlling the overwintering of Pomacea canaliculata in winter soil, reducing the reproduction of Pomacea canaliculata and continuing the northward diffusion of Pomacea canaliculata. The application has important significance for the research and determination of the biology, ecology and new insecticides of Pomacea canaliculata and the mechanism research of the low-temperature tolerance of Pomacea canaliculata.